Tag Archives: David Maris

Wells Fargo Maintains a Hold Rating on Mallinckrodt (MNK)

In a report released today, David Maris from Wells Fargo maintained a Hold rating on Mallinckrodt (MNK – Research Report). The company’s shares closed last Monday at $2.35, close to its 52-week low of $1.43. According to TipRanks.com, Maris has

Wells Fargo Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Wells Fargo analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed last Monday at $133.26. According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars,

Wells Fargo Sticks to Their Buy Rating for Allergan (AGN)

Wells Fargo analyst David Maris maintained a Buy rating on Allergan (AGN – Research Report) today. The company’s shares closed last Monday at $157.87. According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return

Wells Fargo Sticks to Its Buy Rating for Osmotica Pharmaceuticals Plc (OSMT)

In a report released yesterday, David Maris from Wells Fargo maintained a Buy rating on Osmotica Pharmaceuticals Plc (OSMT – Research Report). The company’s shares closed yesterday at $3.05, close to its 52-week low of $2.20. According to TipRanks.com, Maris

Wells Fargo Sticks to Its Hold Rating for Teva Pharmaceutical Industries Limited (TEVA)

Wells Fargo analyst David Maris maintained a Hold rating on Teva Pharmaceutical Industries Limited (TEVA – Research Report) on May 9. The company’s shares closed yesterday at $14.36, close to its 52-week low of $14.04. According to TipRanks.com, Maris is

Wells Fargo Thinks Allergan’s Stock is Going to Recover

In a report released today, David Maris from Wells Fargo maintained a Buy rating on Allergan (AGN – Research Report). The company’s shares closed yesterday at $137.51, close to its 52-week low of $125.84. According to TipRanks.com, Maris ‘ ranking